Back to Search
Start Over
Arginase 1 Is a Marker of Myeloid-Mediated Immunosuppression with Prognostic Meaning in Classic Hodgkin Lymphoma
- Source :
- Blood. 128:1770-1770
- Publication Year :
- 2016
- Publisher :
- American Society of Hematology, 2016.
-
Abstract
- Purpose : Neutrophilia is hallmark of classic Hodgkin Lymphoma (cHL), but its precise characterization remains elusive. We aimed at investigating the immunosuppressive role of high-density neutrophils in HL. Experimental design : First, N-HL function was evaluated in vitro, showing increased arginase (Arg-1) expression and activity compared to healthy subjects. Second, we measured serum level of Arg-1 (s-Arg-1) by ELISA in two independent, training (N=40) and validation (N=78) sets. Results : s-Arg-1 was higher in patients with advanced stage (p=0.045), B-symptoms (p=0.0048) and a positive FDG-PET scan after two cycles of chemotherapy (PET-2, p=0.012). Baseline levels of s-Arg-1 >200 ng/mL resulted in 92% sensitivity and 56% specificity to predict a positive PET-2. Patients showing s-Arg-1 levels > 200 ng/mL had a shorter progression free survival (PFS). In multivariate analysis, PET-2 and s-Arg-1 at diagnosis were the only statistically significant prognostic variables related to PFS (respectively p=0.0004 and p=0.012). Moving from PET-2 status and s-Arg-1 level we constructed a prognostic score to predict long-term treatment outcome: low s-Arg-1 and negative PET-2 scan (score 0, N=63), with a 3-Y PFS of 89.5%; either positive PET-2 or high s-Arg-1 (score 1, N=46) with 3-Y PFS of 67.6%, and both positive markers (score 2, N=9) with a 3-Y PFS of 37% (p=0.0004). Conclusions : We conclude that N-HL are immunosuppressive through increased Arg-1 expression, a potential novel potential biomarker for HL prognosis. Disclosures Vetro: MLL Munich Leukemia Laboratory: Employment. Chiarenza:Gilead: Consultancy; Janssen: Consultancy; Roche: Consultancy.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
Prognostic variable
Myeloid
medicine.medical_treatment
Immunology
Biochemistry
03 medical and health sciences
Internal medicine
medicine
Progression-free survival
Chemotherapy
business.industry
Immunosuppression
Cell Biology
Hematology
medicine.disease
Chemotherapy regimen
Neutrophilia
Leukemia
030104 developmental biology
medicine.anatomical_structure
medicine.symptom
business
Subjects
Details
- ISSN :
- 15280020 and 00064971
- Volume :
- 128
- Database :
- OpenAIRE
- Journal :
- Blood
- Accession number :
- edsair.doi...........db145f21992839956860820472e879ad
- Full Text :
- https://doi.org/10.1182/blood.v128.22.1770.1770